Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2009-03-19
2010-02-09
Wax, Robert A (Department: 1615)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C424S400000
Reexamination Certificate
active
07659290
ABSTRACT:
Provided herein are ready-to-use premixed pharmaceutical compositions of nicardipine or a pharmaceutically acceptable salt and methods for use in treating cardiovascular and cerebrovascular conditions.
REFERENCES:
patent: 3985758 (1976-10-01), Murakami
patent: 4711902 (1987-12-01), Serno
patent: 4880823 (1989-11-01), Ogawa et al.
patent: 4940556 (1990-07-01), MacFarlane
patent: 5079237 (1992-01-01), Husu et al.
patent: 5164405 (1992-11-01), McFarlane et al.
patent: 5198226 (1993-03-01), MacFarlane
patent: RE34618 (1994-05-01), Ogawa
patent: 5376645 (1994-12-01), Stella
patent: 5519012 (1996-05-01), Fercej-Temeljotov
patent: 5904929 (1999-05-01), Uekama
patent: 6595926 (2003-07-01), Laragh
patent: 2007/0112041 (2007-05-01), Bhowmick
patent: 2007/0244166 (2007-10-01), Gupta
patent: 2007/0249689 (2007-10-01), Duncan
patent: 0149475 (1985-07-01), None
patent: 0162705 (1985-11-01), None
patent: 2228412 (1990-08-01), None
patent: WO 01/07086 (2001-02-01), None
Kaise, Barb, et. al., Solutions to Health Care Waste: Life-Cycle Thinking and “green” purchasing, Enviromental Health Perspectives, vol. 109, No. 3, Mar. 2001, pp. 1-4.
Pomponio, R. et. al., Photostability studies on nicardipine-cyclodextrin complexes by capillary electrophoresis, Journal of Pharmaceutical and Biomedical Analysis 35 (2004)267-275.
PDL Biopharma, Inc.; “Cardene IV (nicardipine hydrochloride),” Product Insert, Jan. 2006, USA.
Sweetana and Akers, “Solubility principles and practices for parenteral drug dosage form development,” PDA J Pharmaceutical Science & Technology, 50(5):330-342 (1996).
Zhang et al., “The use of nicardipine for electroconvulsive therapy: a dose-ranging study,” Anesth Analg, vol. 100:378-381 (Feb. 2005).
Endoh et al., “Effects of nicardipine-, nitroglycerin-, and prostaglandin E1-induced hypotension on human cerebrovascular carbon dioxide reactivity during propofol-fentanyl anesthesia,” J Clin Anesth, vol. 11(7):545-549 (Nov. 1999).
Bernard et al., “Long-term hypotensive technique with nicardipine and nitroprusside during isoflurane anesthesia for spinal surgery,” Anesth Analg., vol. 75(2)179-185 (Aug. 1992).
Chen et al., “The comparative potentcy of intravenous nicardipine and verapamil on the cardiovascular response to tracheal intubation,” Acta Anaesthesiol Sin., vol. 34(4)197-202 (Dec. 1996).
Song et al., “Optimal dose of nicardipine for maintenance of hemodynamic stability after tracheal intubation and skin incision,” Anesth Analg, vol. 85:1247-1251 (Dec. 1997).
Cheung et al., “Acute pharmacokinetic and hemodynamic effects of intravenous bolus dosing of nicardipine,” Am Heart J., vol. 119(2 Pt 2):438-442 (Feb. 1990).
Yalkowsky et al., “Formulation-related problems associated with intravenous drug delivery,” J Pharm Sciences, vol. 87(7):787-796 (Jul. 1998).
Maurin et al., “Solubilization of nicardipine hydrochloride via complexation and salt formation,” J Pharm Sciences, vol. 83(10):1418-1420 (Oct. 1994).
Yang et al., “Nicardipine versus nitroprusside infusion as antihypertensive therapy in hypertensive emergencies,” J. Int Med Research, vol. 32(2):118-123 (Mar.-Apr. 2004).
Atlee et al., “The use of esmolol, nicardipine, or their combination to blunt hemodynamic changes after laryngoscopy and tracheal intubation,” Anesth Analg, vol. 90:280-285 (Feb. 2000).
Aya et al., “Intravenous nicardipine for severe hypertension in pre-eclampsia—effects of an acute treatment on mother and foetus,” Intensive Care Med., vol. 25(11):1277-1281 (Nov. 1999).
Cheung et al., “Nicardipine intravenous bolus dosing for acutely decreasing arterial blood pressure during general anesthesia for cardiac operations: pharmacokinetics, pharmacodynamics, and associated effects on left ventricular function,” Anesth Analg, vol. 89:1116-1123 (Nov. 1999).
Colson et al., “Haemodynamic heterogeneity and treatment with the calcium channel blocker nicardipine during phaeochromocytoma surgery,” Act Anaesthesiol Scand., vol. 42(9):1114-1119 (Oct. 1998).
Elatrous et al., “Short-term treatment of severe hypertension of pregnancy: prospective comparison of nicardipine and labetalol,” Intensive Care Med., vol. 28(9):1281-1286 (Jul. 26, 2002).
Fernandes et al., “Physiochemical characterization and in vitro dissolution behavior of nicardipine-cyclodextrins inclusion compounds,” Eur. J. of Pharma. Sci. 15: pp. 79-88, 2002.
Flynn et al., “Intravenous nicardipine for treatment of severe hypertension in children,” J Pediatr., vol. 139(1):38-43 (Jul. 2001).
Kwak et al., “Comparison of the effects of nicardipine and sodium nitroprusside for control of increased blood pressure after coronary artery bypass graft surgery,” J Int Med Res, vol. 32:342-350 (Jul.-Aug. 2004).
Vincent et al., “Intravenous nicardipine in the treatment of postoperative arterial hypertension,” J Cardiothorac Vasc Anesth, vol. 11(2):160-164 (Apr. 1997).
Non Final Office Action for U.S. Appl. No. 11/737,067, dated Oct. 29, 2008.
Duncan Michelle Renee
Gupta Supriya
Haas David Hartley
Stephens Norma V.
Zamiri Camellia
Beckhardt Lyndsey
EKR Therapeutics, Inc.
Lowenstein & Sandler PC
Wax Robert A
LandOfFree
Methods of preparing pre-mixed, ready-to-use pharmaceutical... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of preparing pre-mixed, ready-to-use pharmaceutical..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of preparing pre-mixed, ready-to-use pharmaceutical... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4169872